tiprankstipranks
VitalHub Reports Q3 2022 Financial Results with Record Revenue of $9.8M and Adjusted EBITDA of $2.2M
Press Releases

VitalHub Reports Q3 2022 Financial Results with Record Revenue of $9.8M and Adjusted EBITDA of $2.2M

TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) announced today it has filed its Interim Condensed Consolidated Financial Statements and Management’s Discussion and Analysis report for the three and nine months ended September 30, 2022, with the Canadian securities authorities. These documents may be viewed under the Company’s profile at www.sedar.com.

VitalHub’s Chief Executive Officer Dan Matlow commented,

“Despite Q3 historically having been our seasonally weakest quarter, and notwithstanding the foreign currency headwinds associated with the British pound, Q3 2022 saw continued and consistent improvement across all of our key indicators, quarter over quarter. We continued to grow our organic annual recurring revenue by adding another $850K on a constant currency basis, and achieved another record adjusted EBITDA of $2.2 million for the quarter. With the addition of the Community Data Solutions and Advanced Digital Innovation acquisitions, our ARR stands at close to $34 million. We have significant cash on hand and the availability of a Bank of Nova Scotia Facility, together totaling $48 million available to continue our strategic acquisition strategy, while we continue to generate significant cash from operations that we expect to continue to grow. We have never been in a better position than we are in at the present time.”

VitalHub’s quarterly investor conference call will take place on Friday, November 11, 2022, at 9:00AM EST. To join the call, please dial 1-888-664-6383 (Toll-Free North America) or 416-764-8650 (Local – Toronto) and enter confirmation number 13111266. 

A replay of the call will be available until Friday, December 11, 2022, and can be accessed by dialing 1-888-390-0541 (Toll-Free North America) or 416-764-8677 (Local – Toronto), using the replay entry code 111266#.

Third Quarter 2022 Highlights

  • Revenue of $9,780,553, an increase of $3,161,506 or 48% from the comparative period in the prior year.
  • Gross profit as a percentage of revenue for Q3 2022 was 80% compared to 82% in Q3 2021.
  • ARR (1, 2) at the end of Q3 2022 was $30,967,215.
    • Organic growth of $850,755 or 2.73% from Q2 2022,
    • Reduction of $1,103,048 or 3.53% due to the decrease in the value of the GBP pound relative to the CAD dollar from the prior quarter.
  • EBITDA (2) of $1,389,065 compared to $189,088 in the comparative period in the prior year.
  • Adjusted EBITDA (2) of $2,151,753, or 22% of revenue, compared to $1,277,573 or 19% of revenue in the comparative period in the prior year.
  • Cash on hand at September 30, 2022 was $36,065,885 compared to $16,389,982 as at December 31, 2021.
  • During the quarter, the Company secured additional financing from The Bank of Nova Scotia. Increasing its operating credit limit from $1,000,000 to $6,000,000 and its revolving term facility from $10,000,000 to $27,000,000.
  • Subsequent to the quarter, the Company acquired all of the issued and outstanding shares of QWAD Community Technologies Pty Ltd, doing business as “Community Data Solutions” (“CDS”), a company incorporated and conducting business in Australia. CDS offers an online case management system and supporting products serving 350+ agencies located in all states and internal territories of Australia. Total closing consideration for the acquisition was all-cash for a purchase price at closing of approximately AUD $8,197,155 (CAD $7,110,663), which was after customary closing and working capital adjustments.
  • Subsequent to the quarter, the Company acquired certain assets to maintain the business of Advanced Digital Innovation (UK) Limited (“ADI”) with the product widely known as MyPathway. MyPathway is a digital health platform which is used to improve patient interactions during treatment. Total closing consideration for the acquisition was all-cash for a purchase price of approximately GBP 250,000 (CAD $382,740).
  • Subsequent to the quarter, the Company repaid the balance of its Scotia revolving facility loan in the amount of $8,999,982.
  • With the addition of the ARR(1, 2) of CDS and ADI subsequent to the quarter, the Company’s proforma ARR would be approximately $34,000,000.

Nine Month 2022 Highlights

  • Revenue of $28,681,209, an increase of $10,946,909 or 62% from the comparative period in the prior year.
  • Gross profit as a percentage of revenue for the nine months ended was 82% compared to 79% from the comparative period in the prior year.
  • ARR (1, 2) at September 30, 2022 was $30,967,215 as compared to $21,569,032 at September 30, 2021, an increase of 44%.
  • EBITDA (2) of $ 4,779,798 compared to $645,439 in the comparative period in the prior year.
  • Adjusted EBITDA (2) of $ 7,069,334 as, or 25% of revenue, compared to $ 3,197,090 or 18% of revenue in the comparative period in the prior year.
  • Cashflow from operations before changes in working capital was $5,280,072 for the period as compared to $1,394,927 for the same period last year.

(1) The Company defines annual recurring revenue (“ARR”) as the recurring revenue expected based on yearly subscriptions of the renewable software license fees and maintenance services.
(2) Non-IFRS measure.

Q3 2022 and 2021 Results

                     
  Three months ended Nine months ended
  2022 %
Revenue
2021 %
Revenue
Change 2022 %
Revenue
2021 %
Revenue
Change
  $   $   % $   $   %
Revenue 9,780,553   100% 6,619,047   100% 48% 28,681,209 100% 17,734,300   100% 62%
                     
Cost of sales 1,952,398   20% 1,174,244   18% 66% 5,032,259 18% 3,773,770   21% 33%
                     
Gross Profit 7,828,155   80% 5,444,803   82% 44% 23,648,950 82% 13,960,530   79% 69%
                     
Operating Expenses                    
General and administrative 2,086,415   21% 1,361,762   21% 53% 6,007,993 21% 3,638,214   21% 65%
Sales and marketing 1,076,673   11% 974,506   15% 10% 3,148,312 11% 2,646,543   15% 19%
Research and development 2,622,921   27% 1,875,775   28% 40% 7,365,681 26% 4,328,219   24% 70%
Depreciation 69,992   1% 42,625   1% 64% 173,865 1% 117,314   1% 48%
Depreciation of right-of-use assets 64,158   1% 71,006   1% (10%) 179,640 1% 201,769   1% (11%)
Stock based compensation 289,019   3% 484,226   7% (40%) 872,803 3% 1,088,306   6% (20%)
Foreign currency (gain) loss (109,607 ) (1%) (44,469 ) (1%) 146% 56,573 0% 148,311   1% (62%)
                     
Other Income and Expenses                    
Amortization of intangible assets 847,818   9% 637,685   10% 33% 2,327,016 8% 1,618,502   9% 44%
Business acquisition, restructuring and integration costs 473,669   5% 604,259   9% (22%) 1,416,733 5% 1,463,345   8% (3%)
Interest expense and accretion (net of interest income) (75,059 ) (1%) (7,292 ) (0%) 929% 30,626 0% (25,584 ) (0%) (220%)
Interest income from sublease 0   0% 0   0% 0% 0 0% 0   0% 0%
Interest expense from lease liabilities 72,658   1% 20,856   0% 248% 105,594 0% 64,236   0% 64%
(Gain) loss on disposal of property and equipment 0   0% (344 ) (0%) 100% 1,057 0% 2,153   0% (51%)
                     
Current and deferred income taxes 368,721   4% 0   0% (100%) 410,087 1% 10,071   0% 3972%
                     
Net income (loss) 40,777   0% (575,792 ) (9%) 107% 1,552,970 5% (1,340,869 ) (8%) (216%)
                     
EBITDA(Non-IFRS measure) 1,389,065   14% 189,088   3% 635% 4,779,798 17% 645,439   4% 641%
                     
Adjusted EBITDA(Non-IFRS measure) 2,151,753   22% 1,277,573   19% 68% 7,069,334 25% 3,197,090   18% 121%
                     
Annual Recurring Revenue(Non-IFRS measure) 30,967,215     21,569,032     44% 30,967,215   21,569,032     44%
                     
Recurring revenue(Non-IFRS Measure) 7,657,559   78% 5,462,774   83% 40% 20,623,096 72% 13,960,056   79% 48%
                     
Deferred revenue 15,232,153     8,821,331       15,232,153   8,821,331      
                     
Cash balance 36,065,885     16,389,982       36,065,885   16,389,982      
                     
                     

ABOUT VITALHUB

Software for Health and Human Services providers designed to simplify the user experience & optimize outcomes.

Vitalhub provides technology to Health and Human Services providers including; Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. Vitalhub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination, Patient Flow & Operational Visibility, and DOCit Mobile Apps. The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently, Vitalhub serves 275+ clients across Canada, USA, UK, Australia, Qatar, and Latvia. Vitalhub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The Company is publicly traded on the TSX Venture Exchange under the symbol “VHI”.

CAUTIONARY STATEMENT

This press release includes forward-looking statements regarding the Corporation and its business, which may include, but is not limited to, statements with respect to the appointment of a new directors. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the technology industry, failure to obtain regulatory or shareholder approvals, market conditions, economic factors, the equity markets generally and risks associated with growth and competition. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Corporation undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT INFORMATION

Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
dan.matlow@Vitalhub.com

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles